Use of monoesters of probucol in the treatment of inflammatory diseases

摘要

The invention relates to the use of monoesters of probucol, said monoesters being effective in inhibiting the expression of VCAM-1, in the manufacture of a medicament for the treatment of inflammatory diseases such as human endothelial disorder, asthma, psoriasis, eczematous dermatitis, Kaposi's sarcoma, multiple sclerosis, proliferative disorder of smooth muscle cells, rheumatoid arthritis and osteoarthritis, wherein monoester of probucol is not monosuccinic acid ester of probucol.